Cutting Edge Technology
A Mechanism-Based Approach to Sleep Apnea Therapy
In 2010, a research team led by Dr. Nanduri Prabhakar (co-Founder of Anapneo Therapeutics) reported that respiratory rhythm during hypoxia is regulated by gasotransmitter signaling in the carotid body (see attached scientific paper). In 2017, Dr. Prabhakar’s team reported that sleep apnea can be prevented (and breathing normalized) by inhibiting the enzyme, cystathionine-γ-lyase (CSE), in a preclinical model that accurately recapitulates the phenotype of human sleep apnea (see attached scientific paper).
Targeting this new mechanism of respiratory control, Anapneo scientists have designed and are developing a family of novel compounds to treat sleep apnea and prevent its associated co-morbidities. Anapneo compounds are potent inhibitors of sleep apnea in preclinical models, and act through a mechanism that is present in humans. Our lead compound, TRI-114, is an extraordinarily potent inhibitor of sleep apnea in preclinical models, yet induces no toxicity in any species tested when administered at doses as great as 1000 times its median effective dose.
TRI-114 is in advanced preclinical development; we expect to initiate clinical trials with TRI-114 in 2020. A backup compound, TRI-107, is also a highly potent inhibitor of sleep apnea, and demonstrates a safety profile similar to that of TRI-114. TRI-115 demonstrates potency similar to that of our lead compound, TRI-114, and has desirable pharmacologic and pharmacokinetic characteristics that support its potential development as a therapeutic.
University of Chicago
IIT Research Institute